softwar acquisit boost top line growth
updat forecast estim jul
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research jul
estim jul
price data jul
rate updat jul
currenc amount express
busi strategi outlook
methodolog valu compani
strategi focus provid remot
connect respiratori devic see well place benefit
major healthcar trend promot value-bas
treatment provid care lower cost set
forecast compani gain share usd billion sleep
apnea treatment market reimburs becom
increasingli link evid patient complianc
expect see commerci nation health
insur payor get connect devic band wagon
benefit duopoli philip greatli
recent acquisit softwar servic
platform home healthcar practition new
strateg direct compani alreadi piec
togeth approxim market share usd
strong market posit within
structur grow sleep apnea market volum
growth suffici off-set price
ocash flow robust earn repres
free cash flow preced five year trend
forecast continu
orisk remain around tax issu
subject larg tax charg australia
last two year concern
reflect corpor cultur potenti usd
million plu tax penalti payabl
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
one largest global respiratori medic devic compani
primarili develop suppli flow gener mask accessori
treatment sleep apnea increas diagnosi sleep apnea
combin age popul increas preval obes
result structur grow market compani earn
revenu america balanc across region domin
europ japan australia recent develop acquisit
focus digit health aim differenti
provis clinic data use patient medic care advisor
payor out-of-hospit set
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
key value-
busi strategi outlook jul
take smart devic big data approach
entrench one two lead player
global sleep apnea market strategi two-fold
acceler diagnosi under-penetrated market
monitor patient complianc keep diagnos
patient treatment net payor happier
reimburs cost respiratori devic
global sleep apnea market
penetr structur grow volum around
per year off-set averag price deflat
domin philip togeth make
estim usd billion valu play
key role drive diagnosi at-hom sleep test
devic on-going educ drive creat awar
diseas
remot monitor intellig built
devic provid hook improv patient
complianc clinic effect result
increas usag abil physician adjust
treatment base devic feedback addit payor
increasingli look evid complianc
valid reimburs recent wit
japan franc reimburs link
remot monitor patient complianc despit
mechan posit airway pressur devic littl
chang last year see smart devic
breakthrough given increas focu value-bas
monitor also offer philip technolog set
duo apart smaller player result
see pair strengthen market posit
geographi although
benign price environ next
two year could see margin relief constitut
estim revenu
experienc price deflat per year sinc
medicar competit bid process commenc
temporari gap bid round run
expect price could stabilis improv
near-term profit expect on-going price
deflat compani abl manag given
recent made acquisit home healthcar
softwar platform seek leverag trend
provid care lower cost set brightre acquir
matrixcar acquir offer busi
manag softwar home medic equip
hospic pharmaci home health supplier
estim usd billion market fragment
estim share current
bolt-on acquisit space
long term threat exist respiratori
devic market could come altern therapi
treat sleep apnea howev see emerg
one treatment mandibular devic littl
impact stage typic target patient
persist initi posit airway
pressur devic treatment major
develop horizon
aud fair valu estim factor overal revenu
compound-annual-growth-rate five year fiscal lower
equival trail period growth
boost organ growth acquisit
forecast higher revenu growth america
geographi base market share gain versu
market come high base
result reimburs chang franc
japan softwar servic segment expect
organ growth fiscal report growth
fiscal acquisit absorb
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
normalis ep growth compound fiscal
report ep consequ dividend growth
counter side bear case valuat aud
assum doesnt gain market share major
market price deflat persist result revenu
growth low end market rang
five year forward unsurprisingli scenario would
pressur margin result normal ep compound
growth fiscal report ep
growth period
carv narrow moat global
obstruct sleep apnea osa market base well
recognis consum brand connect
respiratori devic encourag better patient
complianc lead better clinic outcom lower
reimburs risk compani focu creat
connect devic remot monitor patient
usag breath perform entrench
prefer devic provid three user data
patient medic practition payor
patient devic feedback encourag usag allow
get individu care doctor
also abl access payor perspect
evid patient complianc link theme
value-bas healthcar exampl franc nation
health insur link reimburs level directli
key rival philip whose devic similar
function command substanti price premium
less well-known peer philip
compar price price higher
remain peer averag across compar
expect deliv littl oper leverag
revenu mix continu shift favour lower margin
devic softwar rel profit mask
accessori result ebitda oper incom
growth align revenu assumpt
normal ep forecast grow compound
fiscal
demonstr robust top-line despit
experienc price pressur togeth low
financi leverag us reduc cost equiti
averag averag result
compani wacc estim
bull case valuat aud assum price
deflat larg done health insur alreadi
durabl medic
equip space revenu benefit
also provid relief gross margin
scenario estim could expand versu
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
rate moat stabl despit recent
roic believ price
environ benign factor on-going
product deflat per year think
step decreas medicar price play
spend revenu year
stronghold pair philip
osa devic market show sign chang long
term challeng market posit like
come altern therapi smaller
respiratori devic player howev major
higher continu airway pressur cpap
contrast fisher paykel one smaller player
osa devic market chosen focu
devic sale rather pure push high margin
consum product life homecar respiratori
devic typic five year upgrad cycl
fund reimbursor howev new product launch
everi two three year effort get price increas
exist product face annual price deflat
one factor give rise declin
trend howev remain well
wacc factor revenu mix higher margin
mask declin revenu
revenu earn america geographi
remain robust face price deflat
largest import respiratori devic market
medicar make estim market
valu durabl medic equip dme competit
bid process effect kick januari
seen initi step price averag
follow on-going price declin subsequ round
pressur experienc dme
distributor also pass back underli
manufactur benign price environ
expect begin calendar
temporari gap round exist round
effect decemb new round
physic switch cost
consum devic fit univers
may individu custom prefer
noth set mask apart
competit result dont award segment
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
oth resm initi improv sleep apnea
diagnosi could result acceler revenu
growth next five year sleep apnea
market penetr major market
runway growth long
opric risk durabl medic suppli play
pressur could eas go forward result
faster top-line growth expand margin
oth strateg focu data support product
purchas posit well demonstr
valu product healthcar system
oth tax issu came light could suggest
corpor cultur allow question practic
area like sell regul
ofutur cash flow need fund total potenti
histor tax liabil usd million
unproven softwar provid area
current direct lot capit
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
resm strong cash flow net incom
averag convert free cash last five year
allow quickli repay debt fund acquisit
end fiscal report usd billion
gross debt net debt ebitda time margin
elev level rel histori due usd million
acquisit year six
month ebitda includ forecast free cash flow prior
acquisit grow usd million fiscal
usd million fiscal absenc
acquisit compani net cash posit
date net work capit invest remain high
day inventori hand debtor collect day
rang day percentag sale
expect net work capit reduc current
softwar servic start make higher revenu
contribut resm commenc pay dividend
fix pay-out ratio polici fiscal
pay-out ratio forecast rang
pay-out ratio go forward initi
lower acquisition-rel debt paid
assign resm medium uncertainti rate
compani oper regul industri
pressur sell practic also regul
feder anti-kickback statut
reimburs payor allow physician specifi brand
respiratori devic perceiv risk resm
given direct market approach anticip
possibl price relief near-term
temporari gap medicar competit bid round
calendar medium-term on-going innov
requir stem price deflat product portfolio
whole competit risk on-going howev
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
major chang sleep apnea treat
horizon concern tax charg came light fiscal
 agre usd million
payment plan unremit foreign earn
australia tax author assess
underpay tax usd million plu accru
interest usd million fine compani
addit usd million well advis intend
re-audit prior year end fiscal usd
million addit australian tax paid
provis rais outstand amount
 tax full provis tax paid
eight-year payment plan rais new european
legisl govern traceabl medic devic
end patient product perform
warranti come effect may compani
yet disclos anticip effect busi
product warranti provis incur oper
cost maintain central databas neither
anticip materi
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
rate stewardship standard
compani made acquisit histor
increas focu abil execut recent
busi purchas softwar space particularli
compet exist busi built
remain famili run busi ceo michael
farrel son chairman founder
disclos materi transact connect parti
compens formal role ceo
on-going share dilut employe stock option
stock purchas plan scheme compani tri
stem purchas treasuri share
perform relat vest condit disclos
stock option time-bas vest
neg exist sharehold doesnt align
interest manag
repres date owner name posit common share held report holder issuer
share
fund
share
fund
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
state healthcar impact
despit mani australian-list healthcar stock cover
substanti revenu exposur latest
potenti regulatori chang market pose low risk
fair valu estim cost access
healthcar emot topic among voter henc
forefront polit agenda relev
australian compani oper draft
lower health cost act lhcca aim
improv transpar healthcar sector reduc
prescript drug price well presid donald
trump recent execut order transpar
comment cap drug price lowest developed-
australian-list healthcar compani
revenu stream decreas order contribut
report estim mayn pharma
fisher paykel cochlear sonic
healthcar howev revenu risk
price medic devic suppli public health
like fisher paykel cochlear
price diagnost servic provid sonic healthcar
alreadi subject regulatori price action
past year result signific price
pressur devic diagnost like behind us
result focu squar drug price narrow-
moat no-moat mayn pharma expos new
regulatori chang howev quantifi potenti
revenu loss less compani
limit revenu impact result low downsid risk
fair valu estim aud aud
mayn pharma maintain compani
 key market mesoblast research
develop pipelin howev perceiv low
risk price assumpt closest market
product includ fair valu estim aud
leav valuat unchang stage
chang price drug necessarili feed
back directli manufactur know list price
brand drug higher averag
european develop countri benchmark
conclus reach comparison
 intern price top medicar part drug
total expenditur publish depart
human servic octob howev
market extrem opaqu link list
price revenu pharma compani receiv
cost patient directli relat
role play pharmaci benefit manag pbm
collect rebat manufactur pass
patient withdraw propos
rebat rule would requir full pass
rebat commun juli leav
intern price index propos next
consider lower cost drug
estim less loss revenu
intern price index propos implement
propos target physician-administ pharmacy-
dispens self-administ drug suppli medicar
refer part drug base sale includ
studi depart human servic
estim approxim group
revenu studi includ csl privigen intraven
immunoglobulin ivig product comparison
ex-manufactur price part
categori drug conclud price
similar defin within intern
price per gram basi outcom conclud
competitor grifol ivig product gamunex-c grifol
gammagard rate lower price
downward price adjust csl part product would
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
result loss revenu group total
biosimilar also refer lhcca threat
csl plasma product high barrier entri
industri rather patent limit competit
despit earn revenu
estim less possibl loss revenu mayn
pharma implement compani earn
vast major revenu gener product market
price alreadi recent
year revenu brand product
portion may part basket brand
drug distribut mayn pharma exclus
period therefor unlik command major price
premium downward price revis half
brand basket group sale would result
revenu loss result implement
propos would signific impact aud
fair valu estim compani
mesoblast doesnt current earn revenu
howev closest market pipelin product current
fda biolog licens approv process price
estim potenti therapi base competitor
product market lower
equival product japan countri
regist nonetheless major focu
compani drug price reform could pose risk
valuat mesoblast pipelin adjust fair
valu estim stage
healthcare-rel bill current
congress uncertainti law ultim
pass view morningstar healthcar
strategist karen andersen equiti analyst jake strole
unlik implement detail
report juli rebat rule dead suppli chain
benefit drug firm pressur instead expect drug
price reform part medicar product could take
differ form possibl cap out-of-pocket
payment self-administ prescript drug
natur revenu earn mayn pharma
 result low exposur type drug price
reform limit impact fair valu estim
rais fve aud usd jun
rais narrow-moat fair valu estim usd
usd aud aud
australian list increas function temper
medium-term sale forecast off-set lower cost
equiti assumpt averag base
reassess resili low system risk
busi strateg direct creat
allow patient medic
practition payor get clinic complianc
data key view compani entrench
respiratori devic market connect
respiratori devic take increas import
reimburs level franc link evid
patient complianc expect spread
geographi current key rival philip
connect product factor market share
gain five-year compound-annual-growth-rate revenu growth
assumpt ahead estim market growth
larg tax charg book creat artifici low
earn base forecast dilut ep fiscal
usd normal base usd
contrast usd report ep importantli
remain tax risk provis rais
usd million paid across
next eight year usd million usd
million tax penalti claim due australian
author paid rais
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
provis australian tax claim expos
back audit tax year
consensu earn take differ view
oper margin forecast improv
versu consensu expans fiscal
view base revenu mix shift away
profit mask accessori segment given
compani focu lower margin devic softwar
servic acquisit
resm set finish fiscal strongli
share begin screen overvalu
follow releas third-quart result revenu
growth nine month end march broadli
in-lin updat full-year forecast pull
back forecast core devic busi
slightli trail expect
estim remain intact carv narrow
econom moat command domin posit sleep
apnoea expect firm continu bolster share
under-penetrated henc grow market
retain usd per share fair valu estim
fair valu estim australian cdi increas aud
foreign currenc movement
expect devic busi grow mid-single-
digit compound-annual-growth-rate five year fiscal segment
result constitut littl half
revenu less encourag revenu
growth prior correspond period pcp devic
sale under-perform forecast struggl
particularli pronounc europ asia
market compar stronger dollar
reimburs franc japan brought
forward devic upgrad previou quarter caus
slower growth countri last quarter
mask sale repres revenu continu
outpac devic across region number recent
new product releas mask higher margin
core devic busi grow pcp lead
posit mix shift accordingli gross margin expand
basi point bring margin nine
month march full-year
forecast
forecast softwar servic saa segment
grow low-double-digit compound-annual-growth-rate five year
expect saa standout third
quarter howev repres total revenu
quarter saa busi start small
base revenu doubl prior correspond quarter
full quarter contribut recent matrixcar
second quarter
healthcarefirst close first quarter
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
financi summari forecast
fiscal year end june
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
